Changes in the degree of ventricular hypertrophy following administration of Losartan potassium compared to L-NAME (L – Arginine Methyl Ester)

No Thumbnail Available
Muhanad S A
Abdelwahab H M
Osman K A
Journal Title
Journal ISSN
Volume Title
Napata College
Background: The main goal of the study is to investigate the effect of Losartan on the degree of heart hypertrophy compared to L-NAME, also is this changes associated with redistribution of the left ventricular MHCs ratio? Methods: forty six white adult Swiss mice CD1 (weight range between 18g and 33g, and their ages range between 8-10 weeks) were used in this study. Animals were distributed randomly into four groups, each consist of eleven mice as follows: Control group left without treatment during the whole period of the study, group A ( given 600mg/L of L-NAME) , group B (given Losartan potassium 1g/L and L-NAME 600mg/L), and group S ( given 1g/L of Losartan potassium). All treatment were mixed with the drinking water , and given for 35 days. Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used for the separation of the ventricular myocin heavy chains. Results: Administration of Losartan either alone or in combination with L-NAME cause’s significant decreases in the HW/BW ratio with P values 0.000 &0.000 respectively, and this reduction in the degree of the heart hypertrophy shows a shift in α: β ratio towards β LVMHCs compared to control (P values 0.000 &0.001 respectively). While L-NAME treatment in the group A cause’s marginal insignificant increase in HW/BW ratio, P values 0.054, with shifting of α: β MHCs ratio towards β LVMHCs compared to control P values 0.019 . Conclusion: L-NAME treatment changed the LVMHCs from alpha to beta, and this changing occurs before left ventricular hypertrophy. Also treatment with Losartan either alone or in combination with L-NAME produced a shift in the α: β ratio towards β LVMHCs with a decrease in the HW/BW ratio